PT835110E - Utilizacao de (2- imidazolin-2-ilamino) quinoxalinas no tratamento da lesao neural ocular - Google Patents

Utilizacao de (2- imidazolin-2-ilamino) quinoxalinas no tratamento da lesao neural ocular

Info

Publication number
PT835110E
PT835110E PT96923317T PT96923317T PT835110E PT 835110 E PT835110 E PT 835110E PT 96923317 T PT96923317 T PT 96923317T PT 96923317 T PT96923317 T PT 96923317T PT 835110 E PT835110 E PT 835110E
Authority
PT
Portugal
Prior art keywords
imidazolin
quinoxalins
ilamino
utilization
treatment
Prior art date
Application number
PT96923317T
Other languages
English (en)
Portuguese (pt)
Inventor
Larry A Wheeler
Woldemussie Elizabeth
Ronald K Lai
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23971914&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT835110(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of PT835110E publication Critical patent/PT835110E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PT96923317T 1995-06-28 1996-06-17 Utilizacao de (2- imidazolin-2-ilamino) quinoxalinas no tratamento da lesao neural ocular PT835110E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/496,262 US5856329A (en) 1995-06-28 1995-06-28 Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury

Publications (1)

Publication Number Publication Date
PT835110E true PT835110E (pt) 2006-08-31

Family

ID=23971914

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96923317T PT835110E (pt) 1995-06-28 1996-06-17 Utilizacao de (2- imidazolin-2-ilamino) quinoxalinas no tratamento da lesao neural ocular

Country Status (14)

Country Link
US (1) US5856329A (cg-RX-API-DMAC10.html)
EP (3) EP1611891B1 (cg-RX-API-DMAC10.html)
JP (3) JP4621306B2 (cg-RX-API-DMAC10.html)
KR (1) KR19990028403A (cg-RX-API-DMAC10.html)
CN (3) CN1943577B (cg-RX-API-DMAC10.html)
AT (2) ATE322267T1 (cg-RX-API-DMAC10.html)
AU (1) AU715742B2 (cg-RX-API-DMAC10.html)
BR (1) BR9609219A (cg-RX-API-DMAC10.html)
CA (1) CA2225626C (cg-RX-API-DMAC10.html)
DE (2) DE69636012T3 (cg-RX-API-DMAC10.html)
DK (1) DK0835110T4 (cg-RX-API-DMAC10.html)
ES (2) ES2333339T3 (cg-RX-API-DMAC10.html)
PT (1) PT835110E (cg-RX-API-DMAC10.html)
WO (1) WO1997001339A1 (cg-RX-API-DMAC10.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5856329A (en) * 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
WO1999025350A1 (en) * 1997-11-14 1999-05-27 Alcon Laboratories, Inc. Treatment of diabetic retinopathy
US6242442B1 (en) 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions
US6247473B1 (en) 1999-02-18 2001-06-19 Third Millenium Trust System and method for testing the neuroprotective or neuroregenerative effects of drugs
CA2386579A1 (en) * 1999-11-12 2001-05-25 Alcon, Inc. Neurophilin ligands for treating ocular conditions
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
DE10013318A1 (de) * 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
EP1365811A2 (en) * 2000-07-14 2003-12-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
DE10035620B4 (de) * 2000-07-21 2005-07-14 *Acri.Tec Gesellschaft für ophthalmologische Produkte mbH Verwendung von Taurin als neuroprotektives Agens in der Ophthalmologie
WO2002058730A2 (en) * 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
US20030082183A1 (en) * 2000-11-01 2003-05-01 Wheeler Larry A. Methods and compositions for treatment of ocular neovascularization and neural injury
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US7642258B2 (en) * 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
CN1964627B (zh) * 2004-06-04 2011-10-19 华盛顿大学 治疗神经病变的方法和组合物
US7534795B2 (en) * 2005-10-25 2009-05-19 Allergan, Inc. Compounds and their use related to compositions for treating disease
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
CA2641501A1 (en) 2006-02-06 2007-08-16 Nicox S.A. Nitrooxy-comprising derivatives of apraclonidine and brimodnidine as al pha2 -adrenergic receptor agonists
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
AU2008286818B2 (en) * 2007-08-15 2014-03-27 Allergan, Inc. Adrenergic compounds
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
NZ716349A (en) 2009-11-09 2017-07-28 Allergan Inc Compositions and methods for stimulating hair growth
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
EP2956096A1 (en) 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
WO2015129809A1 (ja) * 2014-02-28 2015-09-03 国立大学法人京都大学 虚血性眼疾患の処置用の医薬組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4587257A (en) * 1984-12-14 1986-05-06 Alcon Laboratories, Inc. Control of ocular bleeding using clonidine derivatives
US5021410A (en) * 1989-05-22 1991-06-04 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5180721A (en) * 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5077292A (en) * 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5215991A (en) * 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
DE69425334T2 (de) † 1993-12-17 2001-02-08 The Procter & Gamble Company, Cincinnati 6-(2-imidazolinylamino) chinoxalin-verbindungen als alpha-2-adrenorezeptoragonisten
WO1996013267A2 (en) * 1994-10-27 1996-05-09 Allergan Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma
US5856329A (en) * 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury

Also Published As

Publication number Publication date
EP1611891A3 (en) 2007-03-14
JP2001503370A (ja) 2001-03-13
AU715742B2 (en) 2000-02-10
CA2225626A1 (en) 1997-01-16
US5856329A (en) 1999-01-05
EP1642581A2 (en) 2006-04-05
ATE322267T1 (de) 2006-04-15
DE69636012T2 (de) 2006-11-09
WO1997001339A1 (en) 1997-01-16
EP0835110A1 (en) 1998-04-15
JP2006241138A (ja) 2006-09-14
ES2333339T3 (es) 2010-02-19
AU6386496A (en) 1997-01-30
CN101683343A (zh) 2010-03-31
CN1197391A (zh) 1998-10-28
EP1642581B1 (en) 2009-11-11
KR19990028403A (ko) 1999-04-15
CN1943577B (zh) 2013-06-12
EP0835110B2 (en) 2011-06-15
EP1611891B1 (en) 2012-08-22
DE69636012T3 (de) 2012-01-05
ES2262157T3 (es) 2006-11-16
DK0835110T4 (da) 2011-09-12
BR9609219A (pt) 1999-02-17
DE69638072D1 (de) 2009-12-24
DK0835110T3 (da) 2006-08-14
CN1943577A (zh) 2007-04-11
CA2225626C (en) 2002-09-03
ES2262157T5 (es) 2011-11-10
EP0835110B1 (en) 2006-04-05
ATE447956T1 (de) 2009-11-15
DE69636012D1 (de) 2006-05-18
JP4621306B2 (ja) 2011-01-26
MX9710480A (es) 1998-08-30
JP2011042668A (ja) 2011-03-03
EP1642581A3 (en) 2006-12-27
EP1611891A2 (en) 2006-01-04

Similar Documents

Publication Publication Date Title
BR9609219A (pt) Método de uso de (2-imidazolin-2-ilamino) quinoxalinas no tratamento de lesão neural ocular
CA2357014A1 (en) Method of using (2-imidazolin-2-ylamino) quinoxalines in treating neural injury
AU627626B2 (en) Method for using (2-imidazolin-2-ylamino)quinoxalines to reduce or maintain intraocular pressure
Winkler et al. Oxidative damage and age-related macular degeneration
US6730065B1 (en) Night vision composition
GB9900752D0 (en) Benzimidazole vascular damaging agents
FI970489A7 (fi) Paikallisesti käytettäviä silmälääkekoostumuksia, jotka sisältävät dok sepiinijohdoksia ja soveltuvat allergisten silmäsairauksien hoitoon
WO2001019364A1 (en) A method for optimizing pupil size using alpha antagonist
ES2152556T3 (es) Composiciones que contienen derivados del acido hidroperoxieicosatetraenoico y procedimientos de utilizacion en el tratamiento de trastornos de la sequedad ocular.
Spellacy et al. Glaucoma in a case of Hurler disease
BR9914128A (pt) Composições antibióticas para tratamento do olho, ouvido e nariz
AU5102896A (en) Liposomogenic uv absorbers
AU8160194A (en) Ophthalmic suspension containing diflupredonate
DE69705421D1 (de) 15-fluoro-prostaglandine als augendrucksenkende mittel
ATE60054T1 (de) Neue polyoxygenierte labdan-derivate, verfahren zu ihrer herstellung und ihre anwendung als medikamente.
DE60013126D1 (de) Ophthalmische histamin-enthaltende zusammensetzungen und deren verwendung
AU2001278708A1 (en) Adenosine derivatives and use thereof
ES2118941T3 (es) Composiciones antiglaucoma topicas que comprenden inhibidores de anhidrasa carbonica y bloqueantes beta.
AU4609900A (en) Ophthalmic compositions for the treatment of visual disorders characterised by areduced contrast sensitivity
PT1186302E (pt) Composicao para fazer descer a tensao ocular para administracao topica
TR200003580T2 (tr) Farnesil protein transferazı'nın önlenmesine mahsus benzo(5,6)siklohepta(1,2-B)piridin türevleri
AU7109787A (en) Pyrido(1,2-a) pyrimidine derivatives
AR030879A1 (es) Uso de derivados del acido hidroperoxieicosatetraenoico luego de cirugia refractiva
CO4340602A1 (es) Estructura perfeccionada para gafas protectoras